GlassScriptPhysician profile
Frank Perrino
NPI 1265477244
$8,837.14
in general payments reported to CMS, 2019-2025
47 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,496 · 2020: $383 · 2021: $567 · 2022: $1,411 · 2023: $1,417 · 2024: $1,101 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,980.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,033.54 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $892.05 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $846.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $727.20 | 2019-2025 | |
| Abbvie INC. | $596.31 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $572.36 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $440.86 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $408.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.99 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Dexcom, INC. | $310.51 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $225.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Edwards Lifesciences Corporation | $187.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.43 | 2023-2024 | |
| Exact Sciences Corporation | $178.61 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $166.81 | 2022 |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Perrino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.